• diabetes
  • hypertension
  • sleep apnea
  • heart failure
  • thrombophlebitis
  • pulmonary embolism
  • hyperlipidemia
  • gastroesophageal reflux disease
  • asthma
  • degenerative arthritis
  • pseudotumor cerebri
  • depression
  • venous stasis ulcer
  • infertility
  • Skin Infections

Health Topics Learn about: Your Health

More than 60% of the US population is overweight. Many illnesses are associated with being overweight.

The illnesses associated with obesity are unpleasant. We assist patients in reducing those risks. Simply and softly spoken, if you develop an obesity related illness, the odds are less important, it's 100%, affecting you. A medically supervised diet program is a powerful tool to reach this goal.

We use the BMI as a screening tool to access ones risk for obesity related, co morbid, medical conditions. A patient with an elevated BMI should get a medical evaluation to determine their individual health status.

I. LATENT STAGE: [EARLY]

Insulin Resistance:

  • Genetic Component
  • Environmental component. Modifiable: obesity/sedentary life style. Nonmodifiable: ageing.

Beta Cell Defect: (Dysfunction)

  • Genetic ....... Abnormal processing, storage or secretion.
  • Intracellular/extracellular amylin fibril toxicity. Abnormal processing, storage or secretion.

Intra-Islet Endothelial Absorptive Defect:

  • Heparan sulfate proteoglycan (HSPG) PERLECAN of the capillary endothelial cells avidly attracts amylin (IAPP) and the islet amyloid forms an envelope around the capillary. This is in addition to the increase in the basement membrane associated with the pseudohypoxia (associated with glucotoxicity) and the redox stress within the capillary.

II. TRANSITION STAGE: [MIDDLE]

Persistent Hyperamylanemia

  • Beta cell displacement, dysfunction, mass reduction and diffusion barrier.
  • Continued remodeling of the endocrine pancreas (amyloid).

III. IGT STAGE (Impaired Glucose Tolerance): [LATE]

“Pre-diabetes” Human Health Services (HHS) and American Diabetes Association (ADA) term.

[Start treatment at this time]

[Diagnose earlier: rejuvenation of the 2 hour glucose tolerance blood sugar 140-199 mg/dL]

  • Increased insulin resistance [Feeds forward] > Glucotoxicity [Feeds forward] > Insulin resistance [Feeds forward] > Glucotoxicity: creating a vicious cycle.
  • Islet amyloid. Increasing beta cell defect. Loss of beta cell mass with displacement. (Remodeling of islet architecture including extracellular matrix). Beta cell loss centrally.

IV. IFG STAGE (Impaired Fasting Glucose): [LATER]

“Pre-diabetes” Human Health Services (HHS) and American Diabetes Association (ADA) term.

[Blood sugar ranging 110-126 mg/dL]

[Impaired hepatic glucose production]

  • Increasing global insulin resistance (hepatic) with subsequent gluconeogenesis. Feeding forward in the vicious cycle to accelerate insulin resistance globally.

V. OVERT STAGE: [TOO LATE]

[50% loss of beta cell function]

Va, Vb, Vc. Phases I, II, III: mild, moderate/severe, complete. Use medications that do not increase insulin or amylin. Use combination therapy. Start treatment at stage III-IV (IGT-IFG).

  • Paradigm Shift. Start treatment at the earlier stage of IGT.

Click here to download the entire article as a PDF.

Our Brands